For the first time, a study shows that using an immunomodulatory agent as maintenance therapy prolongs progression-free survival for patients with diffuse large B-cell lymphoma after first-line treatment with rituximab plus CHOP.
A study of pediatric acute lymphoblastic leukemia (ALL) has identified IKZF1 as a new ALL predisposition gene that may play a role both in leukemia pathogenesis and treatment responsiveness.
Ibrutinib can be safely combined with lenalidomide and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma, according to a new study presented at the American Society of Hematology 58th Annual Meeting and Exposition, held December 3–6.
We are speaking with Sonali Smith, MD, an associate professor of medicine and the director of the lymphoma program at the University of Chicago. At the ASH meeting, Dr. Smith will give a talk called “Emerging Biology Leading to New Therapies in Follicular Lymphoma.”
Brentuximab vedotin (BV) induces significantly superior clinical outcomes in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) as compared with physician's choice with methotrexate or bexarotene, according to a new study presented at the American Society of Hematology Annual Meeting & Exposition, held December 3–6, 2016.
Obinutuzumab-based therapy is superior to rituximab-based therapy in patients with previously untreated advanced follicular lymphoma.
Pembrolizumab has good activity, is safe and well-tolerated, and induces durable responses in cutaneous T-cell lymphomas, according to a study presented at the American Society of Hematology Annual Meeting & Exposition.
In this interview, Dr. Ivan Borrello talks about a new approach to treating multiple myeloma at the American Society of Hematology Annual Meeting, held December 3–6, 2016.
As part of our coverage of the ASH Annual Meeting held December 3rd to 6th in San Diego, today we are speaking with Kim Nichols, MD, director of the Cancer Predisposition Division at St. Jude Children's Research Hospital. At this year’s meeting, Dr. Nichols will be participating in a session on genetic susceptibility to leukemia.
At the 11th Annual New York Lung Cancer Symposium, held on November 12, 2016, in New York City, Roman Perez-Soler, MD, spoke about what is currently understood about resistance to EGFR-targeted therapies and how to treat this population of patients.